Geron Corporation
$ 1.27
0.00%
04 Dec - close price
- Market Cap 810,711,000 USD
- Current Price $ 1.27
- High / Low $ 1.28 / 1.25
- Stock P/E N/A
- Book Value 0.39
- EPS -0.12
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.30 %
- 52 Week High 4.08
- 52 Week Low 1.04
About
Geron Corporation is a clinical biopharmaceutical company based in Foster City, California, focused on developing and commercializing innovative therapies for myeloid hematologic neoplasms, notably through its advanced acalabrutinib and telomerase inhibitor programs. With a promising pipeline designed to address significant unmet medical needs in blood cancers, Geron is dedicated to enhancing treatment outcomes for patients. The company stands out for its commitment to pioneering research in hematology, leveraging cutting-edge scientific capabilities to deliver therapies with the potential for transformative clinical impact.
Analyst Target Price
$3.33
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-02-28 | 2023-11-02 | 2023-08-03 | 2023-05-11 | 2023-03-16 |
| Reported EPS | -0.03 | -0.02 | -0.03 | -0.0356 | -0.04 | -0.1 | -0.09 | -0.09 | -0.08 | -0.09 | -0.07 | -0.1 |
| Estimated EPS | -0.0256 | -0.03 | -0.0357 | -0.0464 | -0.08 | -0.1 | -0.1 | -0.1 | -0.1 | -0.08 | -0.1 | -0.12 |
| Surprise | -0.0044 | 0.01 | 0.0057 | 0.0108 | 0.04 | 0 | 0.01 | 0.01 | 0.02 | -0.01 | 0.03 | 0.02 |
| Surprise Percentage | -17.1875% | 33.3333% | 15.9664% | 23.2759% | 50% | 0% | 10% | 10% | 20% | -12.5% | 30% | 16.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GERN
2025-11-05 18:10:00
Geron Corp reported a quarterly adjusted loss of 3 cents per share for the quarter ended September 30, matching analyst expectations but higher than the previous year. Revenue increased by 67.1% to $47.23 million, falling short of analyst predictions. Analysts maintain a "buy" rating on the stock with a median 12-month price target of $4.00.
2025-10-16 01:09:00
Geron Corporation announced leadership changes including the appointment of Ahmed ElNawawi as Executive Vice President and Chief Commercial Officer. These changes are aimed at strengthening RYTELO's U.S. market presence and supporting future portfolio expansion. The article emphasizes that the investment narrative for Geron still hinges on the commercial potential and successful launch of RYTELO, acknowledging the inherent risks of a single-product dependency.
2025-10-14 12:25:01
Geron Corporation announced several board and executive changes, including the resignation of Dr. Gaurav Aggarwal from its Board of Directors and Dr. V. Bryan Lawlis not standing for re-election. Additionally, Dr. Andrew J. Grethlein and Mr. Jim Ziegler will depart from their executive roles. These changes are effective in October 2025 and at the 2026 Annual Meeting.
2025-10-14 08:11:04
Geron (GERN) has announced significant executive changes, including leadership departures and new appointments, aimed at accelerating the commercialization of its blood cancer drug, RYTELO, and strategic growth. Despite a challenging year for shareholders with a 69.3% stock decline, the company's shares are considered significantly undervalued by analysts, trading at $1.27 against a fair value estimate of $3.62, driven by optimism for revenue growth and expanding margins. The success of these changes hinges on effective execution of RYTELO's rollout and positive pipeline developments.
2025-10-13 21:08:29
Geron Corporation (GERN) has announced significant executive leadership changes, including the departure of Andrew Grethlein and Jim Ziegler, and the appointment of Ahmed ElNawawi as Executive VP and Chief Commercial Officer, along with three other executives. These changes are aimed at strengthening commercial and technical operations as the company focuses on advancing its cancer treatment pipeline, particularly Imelstat. While the company demonstrates strong liquidity, financial metrics also indicate challenges with profitability and financial strength, such as a negative Altman Z-Score and a low Piotroski F-Score.
2025-10-13 21:08:27
Geron Corporation (GERN) is implementing executive leadership changes to enhance its commercial focus, with new appointments including a Chief Commercial Officer to drive sales of RYTELO. The biotechnology company, focused on cancer treatments, faces financial challenges despite a strong gross margin, indicated by negative operating and net margins and a distressed Altman Z-Score. Analyst sentiment is cautiously optimistic, reflecting ongoing market volatility and inherent risks within the biotechnology sector.
